Physician profile
Elizabeth Chalom
NPI 1154341147
$4,723.37
in general payments reported to CMS, 2019-2025
38 companies · $868 in 2025
The $868 reported for 2025 was more than what 81% of Pediatric Rheumatology providers received nationally (typical 2025 total: $146).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,123 · 2020: $393 · 2021: $335 · 2022: $504 · 2023: $624 · 2024: $875 · 2025: $868.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,368.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,367.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $988.95 | 2019-2025 | |
| Amgen INC. | $635.02 | 2019-2023 | Enbrel |
| E.R. Squibb & Sons, L.L.C. | $481.67 | 2019-2025 | Orencia |
| Antares Pharma, INC. | $296.30 | 2019-2021 | |
| Pfizer INC. | $214.20 | 2021-2025 | |
| Horizon Therapeutics Plc | $188.71 | 2019-2021 | |
| Genentech USA, INC. | $177.39 | 2019-2025 | Actemra |
| Abbvie INC. | $158.14 | 2019-2025 | Rinvoq, Skyrizi, Humira |
| Novo Nordisk INC | $140.91 | 2022-2025 | Sogroya, Norditropin |
| Ipsen Biopharmaceuticals, INC | $131.98 | 2019-2022 | |
| Glaxosmithkline, LLC. | $121.78 | 2020-2025 | Benlysta |
| Medexus Pharma, INC. | $110.98 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $95.51 | 2019-2024 | Strensiq |
| Azurity Pharmaceuticals, INC. | $87.56 | 2024-2025 | Triptodur, Xatmep |
| Neurocrine Biosciences, INC. | $86.29 | 2024-2025 |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elizabeth Chalom listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.